Precigen, Inc. (PGEN) Reports Phase 1b Study of AG019 ActoBiotics Met Primary Endpoint Assessing Safety and Tolerability

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Precigen, Inc. (PGEN) Reports Phase 1b Study of AG019 ActoBiotics Met Primary Endpoint Assessing Safety and Tolerability
(NASDAQ: PGEN) Delayed: 5.38 +0.56 (11.62%)
Previous Close $4.82    52 Week High $ 
Open $4.89    52 Week Low $ 
Day High $5.39    P/E N/A 
Day Low $5.11    EPS $ 
Volume 8,545,291